Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Mult Scler ; 20(4): 501-4, 2014 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-23986097

RESUMEN

Prompt treatment of neuromyelitis optica (NMO) relapses with steroids or plasma exchange (PLEX) often prevents irreversible disability. The objective of this study is to report the use of intravenous immunoglobulins (IVIG) as treatment for acute relapses in NMO. A retrospective review of 10 patients treated with IVIG for acute relapses was conducted. IVIG was used in the majority of cases because of lack of response to steroids with/without PLEX. Improvement was noted in five of 11 (45.5%) events; the remaining had no further worsening. One patient, a 79-year-old woman, had a myocardial infarction seven days after IVIG. IVIG may have a role in treating acute NMO relapses.


Asunto(s)
Inmunoglobulinas Intravenosas/uso terapéutico , Neuromielitis Óptica/tratamiento farmacológico , Enfermedad Aguda , Adulto , Anciano , Niño , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Prevención Secundaria , Adulto Joven
2.
Hum Mutat ; 34(8): 1111-8, 2013 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-23606453

RESUMEN

Limb girdle muscular dystrophy type 2L or anoctaminopathy is a condition mainly characterized by adult onset proximal lower limb muscular weakness and raised CK values, due to recessive ANO5 gene mutations. An exon 5 founder mutation (c.191dupA) has been identified in most of the British and German LGMD2L patients so far reported. We aimed to further investigate the prevalence and spectrum of ANO5 gene mutations and related clinical phenotypes, by screening 205 undiagnosed patients referred to our molecular service with a clinical suspicion of anoctaminopathy. A total of 42 unrelated patients had two ANO5 mutations (21%), whereas 14 carried a single change. We identified 34 pathogenic changes, 15 of which are novel. The c.191dupA mutation represents 61% of mutated alleles and appears to be less prevalent in non-Northern European populations. Retrospective clinical analysis corroborates the prevalently proximal lower limb phenotype, the male predominance and absence of major cardiac or respiratory involvement. Identification of cases with isolated hyperCKaemia and very late symptomatic male and female subjects confirms the extension of the phenotypic spectrum of the disease. Anoctaminopathy appears to be one of the most common adult muscular dystrophies in Northern Europe, with a prevalence of about 20%-25% in unselected undiagnosed cases.


Asunto(s)
Canales de Cloruro/genética , Distrofia Muscular de Cinturas/genética , Mutación , Adulto , Anciano , Anoctaminas , Canales de Cloruro/metabolismo , Europa (Continente)/epidemiología , Femenino , Variación Genética , Humanos , Masculino , Persona de Mediana Edad , Distrofia Muscular de Cinturas/epidemiología , Distrofia Muscular de Cinturas/metabolismo , Fenotipo , Prevalencia , Estudios Retrospectivos , Factores Sexuales
3.
J Neurol ; 260(8): 2134-7, 2013 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-23689970

RESUMEN

Neuromyelitis optica (NMO) is an uncommon, demyelinating disease that causes long-term disability in adults. Though much has recently been learned about its pathogenesis, there are still only a few studies regarding the epidemiology of NMO. The aim of the study was to describe the epidemiology of NMO among adults in the Merseyside county of the United kingdom. Multiple overlapping sources of data were used including hospital records of The Walton Centre for Neurology and Neurosurgery in Liverpool, regional district general hospital data, central Aquaporin-4 antibody testing laboratory data and the British Neurological Surveillance Unit- to identify adults with a first-ever-in-a-lifetime diagnosis of NMO. As of December 31, 2010, there were eight cases (five NMO; three NMO spectrum disorder), indicating a prevalence of 7.2/million (95 % CI 3.1-14.2). Four incident cases of NMO and three incident cases of NMO spectrum disorder were identified in this period, indicating a minimum combined average annual incidence rate of 0.8/million (95 % CI 0.3-1.6). NMO still remains an uncommon condition, but the prevalence is rising with early diagnosis.


Asunto(s)
Neuromielitis Óptica/epidemiología , Anciano , Acuaporina 4/inmunología , Acuaporina 4/metabolismo , Biomarcadores , Humanos , Persona de Mediana Edad , Neuromielitis Óptica/genética , Vigilancia de la Población , Prevalencia , Factores Socioeconómicos , Reino Unido/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA